|
|
|
|
||
BoA ML..Health Care key themes and top pick updateBiotechnology: Buy CELG, BLUE, OREX Our top large-cap pick is CELG, as we expect continued strong growth for Revlimid and a potential settlement with Natco/Actavis this year. For smid-cap biotech, we like BLUE, which could see meaningful upside if LentiGlobin updates in betathalassemia and sickle cell disease are positive this June, and OREX, where we expect continued strong script growth for Contrave and a near-term EU approval
followed by a potential ex-US partnership and life cycle extension opportunities. Top Biotech Picks for 2015
Top Large-Cap Biotech Pick: Celgene (CELG) Our top large-cap pick for 2015 is CELG, one of the highest growth large-cap biotech companies with a diverse and robust pipeline that supports future growth. We anticipate continued strong growth for its flagship product Revlimid, driven by share gains, longer duration of therapy, and label expansions (the drug recently gained approval for use in newly diagnosed multiple myeloma). Another key catalyst for CELG in 2015 is the potential settlement of the ongoing Revlimid patent case with Natco/Actavis. We would view a settlement as favorable for CELG if the company concedes 1-3 years of patent life, as it would remove a significant overhang on the stock.
|
return to message board, top of board |